Get started

Emergent Biosolutions, Inc

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

EBS chart

Key stats

Market capitalization
415.691MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−8.05USD

About Emergent Biosolutions, Inc

Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Robert G. Kramer
Website
emergentbiosolutions.com
Headquarters
Gaithersburg
Employees
2.5K
Founded
1998
ISIN
US29089Q1058

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Ideas

$EBS - Narcan over the counter nose spray & Earnings 2/27I usually stray away from bio/biotech b/c of how volatile it is, but $EBS seems to be established with a $800M+ market cap, strong historicals, 20 PE ratio, and seems to be getting close to bottom. They also have an exciting narcan nasal spray product that can be sold over the counter they are worki
1
EBS long 12.00-9.00$The price is approaching the strong level of $10.60, and there is already increased interest in this stock. This stock has been showing growth in December for many years, so it makes sense to consider buying in the $12.00-9.00 area, stop-loss at $8.5. The first target is $25, the second target is $3
Long
Is EBS a buy as it hits a critical support level? EBS is currently hitting a critical support level around the 25 levels, which has been tested multiple times as key support and resistance level since 2009. I am planning on buying at this current level, with a very high-profit target and a tight 5% stop loss below the support level. The ATH is ov
Long
EBS: It's pretty bad when you underperform TNXPConsidering TNXP does... well... nothing, EBS underperforming TNXP is disappointing. Still holding and will continue to buy shares if SP falls back into the gray area at $25-$32. Monthly hammer + continuation off a high volume node + 2.618 fib should indicate a trend reversal. EBS was never a "sque
Long
EBS: FEAR THE MONKEYPOX!Apparently, there will be a WHO meeting next meeting concerning how serious Monkey Pox is going to be. Potential Long Term Head and Shoulders forming. $25 is a long term support level and Monthly VPOC. Speculative trade back to the 200W MA at $60
Long
7
EBS - Head and Shoulders Pattern, Weekly1/1 line is a major Trend line Using the Fib circles the H&S pattern becomes more evident with the LS being rejected at the 1 level The H being formed at 1.618 and the RS being formed in the aftermath of the H formation I expect more downsides on this weekly timeframe until the strong support level
EBS ScalpJust broke trend, but long-term support below. I expect it to bounce and backtest the old trend, but no clue after. Could fall to $40 fib then maybe lower. I love this as a long at some point though. Company got bad press and missed a COVID vaccine delivery after a factory was shut down. It's
Long

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.

Financials

Performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.45Fabulous
Learn more
OANDA
OANDA
Forex
4.52Great
Learn more
FOREX.com
FOREX.com
Forex
4.36Fabulous
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.35Fabulous
Learn more

See all brokers 

Gain new superpowers

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn more